Fabian Noti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9768011/publications.pdf

Version: 2024-02-01

1040056 1058476 24 227 9 14 citations h-index g-index papers 25 25 25 296 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Validation of a multipolar pulsed-field ablation catheter for endpoint assessment in pulmonary vein isolation procedures. Europace, 2022, 24, 1248-1255.	1.7	16
2	Differences in Atrial Remodeling in Hypertrophic Cardiomyopathy Compared to Hypertensive Heart Disease and Athletes' Hearts. Journal of Clinical Medicine, 2022, 11, 1316.	2.4	4
3	Leadless atrioventricular synchronous pacing in an outpatient setting: Early lessons learned on factors affecting atrioventricular synchrony. Heart Rhythm, 2022, 19, 748-756.	0.7	30
4	Dexmedetomidine versus propofol for operator-directed nurse-administered procedural sedation during catheter ablation of atrial fibrillation: A randomized controlled study. Heart Rhythm, 2022, 19, 691-700.	0.7	12
5	A second chance to make a first impression $\hat{a}\in$ Parylene C residuals staining the surface of cardiac implantable electronic devices. Heart Rhythm, 2022, , .	0.7	O
6	Evolution of tricuspid valve regurgitation after implantation of a leadless pacemaker: A single center experience, systematic review, and metaâ€analysis. Journal of Cardiovascular Electrophysiology, 2022, 33, 1617-1627.	1.7	11
7	The Relationship between Enhancing Left Atrial Adipose Tissue at CT and Recurrent Atrial Fibrillation. Radiology, 2022, 305, 56-65.	7.3	9
8	Unexpected high failure rate of a specific MicroPort/LivaNova/Sorin pacing lead. Heart Rhythm, 2021, 18, 41-49.	0.7	10
9	The SilenT AtRial FIBrillation (STAR-FIB) study programme – design and rationale. Swiss Medical Weekly, 2021, 151, w20421.	1.6	3
10	Efficacy and safety of ethanol infusion into the vein of Marshall for mitral isthmus ablation. Journal of Cardiovascular Electrophysiology, 2021, 32, 1610-1619.	1.7	8
11	Reply toâ€"MicroPort CRM considerations on Beflex/Vega pacing lead performance. Heart Rhythm, 2021, 18, 1634-1635.	0.7	0
12	Age and Sex Specific Prevalence of Clinical and Screen-Detected Atrial Fibrillation in Hospitalized Patients. Journal of Clinical Medicine, 2021, 10, 4871.	2.4	4
13	Outcome of video-assisted thoracoscopic implantation of epicardial left ventricular leads with visual targeting for cardiac resynchronization therapy. Interactive Cardiovascular and Thoracic Surgery, 2020, 30, 373-379.	1.1	1
14	High incidence of diaphragmatic myopotential oversensing by a specific implantable cardioverter defibrillator. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 234-239.	1,2	0
15	Leadless pacemaker implantation quality: importance of the operator's experience. Europace, 2020, 22, 939-946.	1.7	15
16	Cardiac Implantable Electronic Device–Related Infection Due to Granulicatella adiacens. Open Forum Infectious Diseases, 2019, 6, ofz130.	0.9	3
17	Usefulness of Genetic Testing in Sudden Cardiac Arrest Survivors With or Without Previous Clinical Evidence of Heart Disease. American Journal of Cardiology, 2019, 123, 2031-2038.	1.6	30
18	How to Reach the Left Atrium in Atrial Fibrillation Ablation?. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006744.	4.8	1

Fabian Noti

#	Article	IF	CITATION
19	Comparison of lead failure manifestation of Biotronik Linox with St. Jude Medical Riata and Medtronic Sprint Fidelis lead. Journal of Interventional Cardiac Electrophysiology, 2019, 54, 161-170.	1.3	7
20	Leadless cardiac resynchronization therapy: An inÂvivo proof-of-concept study of wireless pacemaker synchronization. Heart Rhythm, 2019, 16, 936-942.	0.7	12
21	Phenotypic Spectrum of <i>HCN4</i> Mutations. Circulation Genomic and Precision Medicine, 2018, 11, e002033.	3.6	18
22	Unexplained Cardiac Arrest in an Apparently Healthy Young Woman. Circulation, 2018, 137, 1863-1866.	1.6	2
23	Unexplained cardiac arrest: a tale of conflicting interpretations of KCNQ1 genetic test results. Clinical Research in Cardiology, 2018, 107, 670-678.	3.3	6
24	Failure rate and conductor externalization in the Biotronik Linox/Sorin Vigila implantable cardioverter-defibrillator lead. Heart Rhythm, 2016, 13, 1075-1082.	0.7	25